Resumen
There is a pressing need for new effective treatments against glioma. A promising option is a class of drugs called poly(ADP-Ribose) polymerase (PARP) inhibitors. PARP inhibitors block the repair of DNA damage. They may work synergistically with radiotherapy, chemotherapy and immunotherapy. They may work particularly well in settings where other DNA damage repair pathways are impaired. This article reviews the clinical trials investigating PARP inhibitors in glioma.